• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Intera Oncology has a serious infusion pump recall

August 29, 2022 By Sean Whooley

Intera Oncology Intera 3000 infusion pump
[Image from Intera Oncology’s website]
The FDA today warned that the recall of an infusion pump from Intera Oncology is Class I, the most serious kind.

Intera recalled the Intera 3000 hepatic artery infusion pump after receiving reports from clinicians that the pumps were delivering medications (flow rate) faster than expected. If the pump delivers infusions at faster than expected flow rates, the patient may receive too much medication at one time, resulting in life-threatening hematologic (myelosuppression) toxicity, neurotoxicity or death.

Additionally, if the flow rate is too fast, the patient may run out of medication before a pump refill occurs, which may allow their disease to progress or lead to death.

According to the FDA notice, the company initiated the recall on July 10, 2022. It affects 440 devices that were distributed in the U.S. between Aug. 12, 2021, and May 17, 2022. To date, Intera has received reports of three incidents related to the issue, with no reports of injuries or death.

The Intera 3000 hepatic artery infusion pump continuously delivers medicine through the hepatic artery, which supplies blood and oxygen to the liver and several other organs. The pump is implanted in adult patients and delivers chemotherapy medications that treat liver tumors, with users capable of returning to daily activities with pump refills performed at the hospital every two weeks.

Intera’s recall notice told customers to monitor flow rates per standard refill procedure and monitor for liver toxicity to adjust dosing as per standard protocols.

Users should consider pump replacement if the altered flow rate of the pump can’t be adequately managed by dosing adjustments of the infusate when hepatic artery infusion therapy needs to continue, Intera instructed. They should also consider verifying their flow rate sooner than every two weeks if the pump appears to be flowing more than 15% outside of the labeled specification.

Customers may also look to flush the bolus pathway with low dose heparinized saline (100 IU/ml) using the special bolus needle if the pump is empty at the time of refill, while their care team should decide whether to inform the patient of the possibility of alterations in flow.

Filed Under: Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Recalls, Regulatory/Compliance Tagged With: Intera Oncology

IN CASE YOU MISSED IT

  • Insulet hires new chief HR officer from J&J
  • Breakthrough T1D, Mattel debut Barbie doll with type 1 diabetes
  • Medtronic Diabetes names CFO with consumer experience ahead of separation
  • Diabeloop launches insulin delivery algorithm in Germany
  • GlucoModicum has positive data for needle-free CGM

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS